ArticleOpen biology2020
Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p.
Article in Open biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux.Experimental hematology & oncology · 2025Article
- A fishnet between nasopharyngeal carcinoma and resistance: the competing endogenous RNA network.Current treatment options in oncology · 2025Review
- [Dihydroartemisinin enhances sensitivity of nasopharyngeal carcinoma HNE1/DDP cells to cisplatin-induced apoptosis by promoting ROS production].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer.Reproductive biology and endocrinology : RB&E · 2022Article
- Upregulation of VDR-associated lncRNAs in Schizophrenia.Journal of molecular neuroscience : MN · 2022Article
- Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.International journal of biological sciences · 2022Review
- Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma.Frontiers in oncology · 2022Review
- The Role of lncRNAs in Rare Tumors with a Focus on HOX Transcript Antisense RNA (International journal of molecular sciences · 2021Review
- HOXA11-AS induces cisplatin resistance by modulating the microRNA-98/PBX3 axis in nasopharyngeal carcinoma.Oncology letters · 2021Article
- Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer.Biomedicines · 2021Review
- LncRNA FOXD3-AS1 Promotes the Malignant Progression of Nasopharyngeal Carcinoma Through Enhancing the Transcription of YBX1 by H3K27Ac Modification.Frontiers in oncology · 2021Article
- A Five-MicroRNA Signature Predicts the Prognosis in Nasopharyngeal Carcinoma.Frontiers in oncology · 2021Article
- Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Nasopharyngeal Carcinoma.Cancer management and research · 2021Review
- New Insights into LINC00346 and its Role in Disease.Frontiers in cell and developmental biology · 2021Review
- Review
- Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma.Diagnostics (Basel, Switzerland) · 2020Review
Corrections and comments
- Expression of concern · 2023-08-31Concerns/Issues about Data · Investigation by Journal/Publisher · Updated to Retraction ·
- Retraction · 2023-11-03Duplication of/in Article · Duplication of Data · Euphemisms for Duplication · Investigation by Journal/Publisher · Unreliable Data · Upgrade/Update of Prior Notice(s) ·
- Expression of concern
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin has been used as the first-line chemotherapy to treat advanced nasopharyngeal carcinoma (NPC), while acquired cisplatin resistance resulting from epigenetic regulation is not well understood. The relative expression of LINC00346 was detected in healthy persons, cisplatin-sensitive (CS) patients and cisplatin-resistant (CR) patients. The regulatory effect of LINC00346 on the proliferation was detected by cell-counting kit-8. Apoptosis was assayed by histone/DNA ELISA and Caspase-3 activity. Clonal formation and cisplatin resistance were also deciphered. Luciferase reporter and RNA immunoprecipitation assay were adopted to study the interaction between LINC00346 and miR-342-5p. LINC00346 was highly expressed in NPC patients, especially in CR patients, which was associated with cisplatin resistance and poor prognosis. Inhibition of LINC00346 expression promoted cisplatin sensitivity of NPC cells, while LINC00346 over-expression promoted cisplatin resistance of NPC cells. miR-342-5p expression was negatively correlated with cisplatin resistance, and microRNA-342-5p siRNAs treatment could rescue the cisplatin resistance diminished by LINC00346 inhibition. It was further found that miR-342-5p was negatively regulated by LINC00346. In conclusion, LINC00346 regulates the cisplatin resistance of NPC cells by inhibiting miR-342-5p, which could provide a potential target for chemotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.